Stilla, a pioneer in the field of genomics and digital PCR, is excited to announce its expansion in the United States via a strategic distribution relationship with Avantor, a global leader in life sciences and advanced technology solutions. Through this arrangement, Stilla’s comprehensive product range for digital PCR will now be readily accessible to customers across the USA, further enriching Avantor’s genomics core portfolio. This expansion facilitates the distribution of Stilla’s cutting-edge solutions through Avantor’s dedicated Life Sciences specialist team, streamlining access for researchers and clinicians alike.
Kerri McWeeny, GM North America from Stilla, expressed enthusiasm about the relationship, stating, “This collaboration implies a significant milestone for Stilla as we penetrate the USA market. With Avantor’s backing, we are well-positioned to achieve our biopharma, applied testing, and academia objectives while enhancing our applications to better serve our customers.” Moreover, Stilla proudly announces the expansion of its content offerings to meet the evolving needs of its clientele.
With a focus on Cell and Gene Therapy, biopharma quality control, infectious diseases, and applied testing, Stilla aims to provide comprehensive solutions addressing critical challenges in research and diagnostics. Dr. Afif Abdel Nour, VP of Global Marketing at Stilla, reiterated the company’s commitment to advancing precision medicine through innovation, stat.
